SSII · CIK 0001676163
What SS Innovations International, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for SSII. More may follow as additional filings are processed.
In its own words
What could break it.
Geographic concentration
- India ~87% of revenue + sole manufacturing sitehigh
Highly concentrated in India: ~87% of FY2025 revenue from within India, and all systems/instruments designed and manufactured at its single Gurugram, India facility.
“The systems as well as instruments and accessories are primarily designed, developed and manufactured by the Company in its manufacturing facility located in India. During the year ended December 31, 2025, and 2024, the Company's revenues from within India accounted for 87 % and 92 % respectively of total revenue, while revenue from the Company's markets outside India accounted for 13 % and 8 %, respectively, of total revenue.”
Regulatory & policy
- pending EU/US regulatory approvals (CDSCO-approved India only)medium
International expansion of the SSi Mantra surgical robot depends on EU and U.S. regulatory approvals anticipated in 2026, with no assurance they will be obtained; currently only CDSCO-approved for India.
“We are currently focusing our efforts on marketing our latest generation SSi Mantra 3 in international markets and anticipate receiving EU and U.S. regulatory approvals to market in those regions in 2026, however, there can be no assurance as to when or if we will secure such regulatory approvals.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch